Bornavirus Encephalitis Shows a Characteristic Magnetic Resonance Phenotype in Humans

Tom Finck, MD,1† Friederike Liesche-Starnecker, MD,2† Monika Probst, MD,1 Stefanie Bette, MD,3 Viktoria Ruf, MD,4 Christina Wendl, MD,5 Franziska Dorn, MD,6 Klemens Angstwurm, MD,7 Jürgen Schlegel, MD,2 Claus Zimmer, MD,1 Benedikt Wiestler, MD,1‡ Isabel Wiesinger, MD,5‡ and the Bornavirus-Encephalitis Study Group

Objective: The number of diagnosed fatal encephalitis cases in humans caused by the classical Borna disease virus (BoDV-1) has been increasing, ever since it was proved that BoDV-1 can cause human infections. However, awareness of this entity is low, and a specific imaging pattern has not yet been identified. We therefore provide the first comprehensive description of the morphology of human BoDV-1 encephalitis, with histopathological verification of imaging abnormalities.

Methods: In an institutional review board-approved multicenter study, we carried out a retrospective analysis of 55 magnetic resonance imaging (MRI) examinations of 19 patients with confirmed BoDV-1 encephalitis. Fifty brain regions were analyzed systematically (T1w, T2w, T2*w, T1w + Gd, and DWI), in order to discern a specific pattern of inflammation. Histopathological analysis of 25 locations in one patient served as correlation for MRI abnormalities.

Results: Baseline imaging, acquired at a mean of 11 ± 10 days after symptom onset, in addition to follow-up scans of 16 patients, revealed characteristic T2 hyperintensities with a predilection for the head of the caudate nucleus, insula, and cortical spread to the limbic system, whereas the occipital lobes and cerebellar hemispheres were unaffected. This gradient was confirmed by histology. Nine patients (47.4%) developed T1 hyperintensities of the basal ganglia, corresponding to accumulated lipid phagocytes on histology and typical for late-stage necrosis.

Interpretation: BoDV-1 encephalitis shows a distinct pattern of inflammation in both the early and late stages of the disease. Its appearance can mimic sporadic Creutzfeldt–Jakob disease on MRI and should be considered a differential diagnosis in the case of atypical clinical presentation.

ANN NEUROL 2020;88:723–735

View this article online at wileyonlinelibrary.com. DOI: 10.1002/ana.25873

Received May 20, 2020, and in revised form Aug 5, 2020. Accepted for publication Aug 7, 2020.

Address correspondence to Dr Wiesinger, MD, Department of Radiology, Center of Neuroradiology, University Hospital Regensburg, Regensburg, Germany. E-mail: isabel.wiesinger@medbo.de

†T.F. and F.L.-S. contributed equally
‡I.W. and B.W. contributed equally

From the 1Department of Diagnostic and Interventional Neuroradiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; 2Department of Neuropathology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; 3Department of Diagnostic and Interventional Radiology and Neuroradiology, Augsburg University Hospital, Augsburg, Germany; 4Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universität München, Munich, Germany; 5Department of Radiology, Center of Neuroradiology, University Hospital Regensburg, Regensburg, Germany; 6Department of Diagnostic and Interventional Neuroradiology, Ludwig-Maximilians-Universität München, Munich, Germany; and 7Department of Neurology, Regensburg University Hospital, Regensburg, Germany

Additional supporting information can be found in the online version of this article.

© 2020 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. 723 This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Introduction
Recently, it has been demonstrated that the classical Borna disease virus (BoDV-1; species *Mammalian 1 orthobornavirus*) can lead to encephalitis in humans that is usually fatal.1–4 Consequently, the numbers of both retrospectively detected and recent cases are increasing. To date, a lack of awareness of the disease and its clinical spectrum delay correct diagnosis and impede adequate therapy.

In animals, including horses and sheep, in which BoDV-1 infection has been known for centuries, typical neurological manifestations and distribution patterns have broadly been described.6,7 For the most part, behavioral changes, including leg crossing and scratching, are observed. In the late stage, paralysis, blindness, and coma resulting in death occur in most cases.6 Typically, the olfactory bulbs and hippocampus are affected, explaining why the olfactory system is believed to be a possible entry point in animals.7

In humans, the disease often starts with unspecific flu-like symptoms, followed by a broad variety of neurological symptoms, including gait ataxia, dysphagia, blurred speech, epileptic seizures, and hemiparesis.5 A systematic neuropathological analysis of autopsy material of 6 patients with confirmed BoDV-1 encephalitis provided the first hints that the distribution pattern might differ from what we know in animals. An accentuation of the basal nuclei was described for two deceased patients.1 Analysis of autopsy material is, however, limited by the fact that only the end stage of the disease can be evaluated. Life-prolonging therapies might have influenced these findings, especially regarding the distribution pattern. In contrast, magnetic resonance imaging (MRI) offers the chance to follow the course of the disease to gain a better understanding of the starting point and spread of the inflammation. From this point of view, discerning a specific pattern on MRI could accelerate the identification of affected patients and thus facilitate differentiation from other rapidly deteriorating conditions, such as similar encephalitis pathogens or prion-related disease.

Patients and Methods
Data Acquisition and Virus Detection
In this study, we evaluated 55 brain MRI examinations from 19 patients with confirmed postmortem diagnosis of human BoDV-1 encephalitis and included data from 4 university hospitals, one general hospital, and two community hospitals in southern Germany. No spinal imaging was available for review. For all patients, the presence of BoDV-1 RNA had been confirmed by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR), as described earlier.3 Additionally, in 13 patients, the diagnosis of BoDV-1 encephalitis was corroborated by immunohistochemistry against the nucleoprotein of BoDV-1 and BoDV-1 RNA in situ hybridization of brain tissue samples, as described previously.1 Removal of patient-linked metadata and defacing of the MRI images for anonymization took place before evaluation of scans. Although data on Patient 4 (P3 of Liesche and colleagues1), Patient 7 (P2 of Liesche and colleagues1; P6 of Coras and colleagues2), Patient 8 (P1 of Liesche and colleagues1), Patient 9 (P5 of Liesche and colleagues1), Patient 16 (P4 of Liesche and colleagues1; P7 Coras and colleagues2), Patient 11 (Recipient 1 of Schlottau and colleagues3), Patient 14 (P2 Coras and colleagues2), Patient 15 (P6 of Liesche and colleagues1; P8 Coras and colleagues2), and Patient 17 (P3 Coras and colleagues2) have been reported previously, the focus in the preceding studies was set on clinical information and not imaging findings. The local ethic committees of the respective institutions approved this retrospective study (577/19 S-SR and 560/19 S-KH).

Systematic Scan Evaluation
The magnetic resonance (MR) images were analyzed retrospectively, independently and in random order, by two neuroradiologists (T.F and I.W., with MRI experience of 3 and 7 years, respectively) blinded for the scanning time point or any clinical data beyond the fact that diagnosis of BoDV-1 encephalitis had been confirmed. A standardized scheme was defined to investigate 50 previously defined brain regions (a list of evaluated regions is given in supplementary Table S1) deemed anatomically and functionally relevant. After binary determination of whether a brain region showed any abnormalities, the intraparenchymal location of an anomaly into cortical, subcortical, deep white matter, or the basal ganglia was defined. Next, the morphology and quality of a particular lesion were classified based on its delineation, mass effect, and signal alterations on T1w/T2w/T2*w, lack/presence of diffusion restriction, lack/presence of contrast enhancement, or any combination of these signal changes. Raters were also asked to determine whether changes were suggestive of laminar necrosis, as defined by native T1 hyperintensity of the cortical band.8 In divergent primary ratings, a consensus rating was reached by involving a third neuroradiologist (M.P.) with 10 years of experience.

Histopathology, Immunohistochemistry, and RNA In Situ Hybridization
From a representative patient for whom the formalin-fixed whole-brain specimen was available (bilateral if applicable and not specified otherwise), tissue samples from 25 locations (head of the caudate nucleus, striatum, globus pallidus, insula, thalamus [right], hippocampus [left],
occipital cortex, frontal cortex [right], parietal cortex [left],
cerebellar vermis, cerebellar hemisphere, deep white matter
[occipital], temporal pole [right], mesencephalon, and
leptomeninx) were retrieved for histopathological evalu-
ation. After paraffin embedding, 2μm-thick sections were
sliced and stained with Hematoxylin and Eosin (H&E).

For immunohistochemistry, an established avidin–
biotin complex technique was performed. Pretreatment in
pH 6.0 citrate buffer at 95°C for 30 minutes for epitope
uncovering and H2O2 were followed by overnight incuba-
tion with the primary antibodies against GFAP (Dako
Denmark A/S, Glostrup, Denmark; polyclonal, rabbit,
dilution 1:500), Iba1 (abcam, Berlin, Germany; poly-
clonal, rabbit, dilution 1:500), CD45 (DCS Innovative
Diagnostik-Systeme, Hamburg, Germany; monoclonal,
mouse, clones 2B11 and PD7/26, dilution 1:250) and
Iba1 (abcam, Berlin, Germany; polyclonal, rabbit,
dilution 1:500), CD68 (Dako Denmark A/S, Glostrup, Denmark; monoco-
nal, mouse, clone KP1, dilution 1:1,500).

For evaluation of virus distribution, a monoclonal
antibody against the nucleoprotein of BoDV-1 was used,
as described previously.1 Afterwards, biotinylated second-
ary antibodies were applied for 30 minutes, followed by
incubation with avidin–biotin–complex and dia-
minobenzidine reagents. Finally, counterstaining with
Hematoxylin was conducted. Additionally, BoDV-1 RNA
in situ hybridization with the probe V-BoDV1-G
targeting 2-969 of NC_001607-1:2236-3747 (RNAscope;
Advanced Cell Diagnostics, Newark, CA) was performed
on a selection of 11 locations (bilateral if applicable and
not specified otherwise; head of the caudate nucleus, stri-
tatum [right], insula, thalamus, hippocampus, parietal cor-
tex [right], occipital cortex [left], frontal cortex [left],
cerebellar vermis, cerebellar tonsils, and mesencephalon)
as described previously.9 Positive controls served as quality
assurance for all immunohistochemical stains and the
RNA in situ hybridization.

**Histopathological Evaluation**

Histopathological evaluation was performed by a highly
experienced neuropathologist (F.L.-S.). The density of
pathognomonic Joest–Degen bodies10 was determined by
counting the number of inclusions in 10 high-power fields
(HPFs; ocular: ×10/23; objective: ×40/0.75). The severity
of edema was evaluated semiquantitatively by establishing a
score ranging from 0 (no edema) via 1 (mild) and 2 (moder-
ate) to 3 (severe edema). The virus distribution was evalu-
ated by counting BoDV-1+ cells in immunohistochemistry,
extrapolating to a standardized tissue size of 1 cm². Furthe-
more, cells with positive BoDV-1 RNA signal were counted
and also standardized to a tissue size of 1 cm².

For the evaluation of reactive astrogliosis and activ-
ated microglial cells, the average of GFAP+ (GFAP is
defined as glial fibrillary acidic protein) reactive astrocytes
and Iba1+ (Iba1 is defined as ionized calcium-binding
adapter molecule 1) activated microglial cells, respectively,
was calculated in 5 HPFs. All diffusely distributed CD45+
lymphocytes and CD68+ macrophages were counted and
extrapolated. Furthermore, the severity of perivascular
infiltration was determined by counting perivascularly
located CD45+ cells in 5 transversely cut vessels with simi-
lar diameter.

Twenty-five brain regions of Patient 4, who was
included in a previous study,1 were analyzed regarding the
severity of edema, astrogliosis, microglial activation, and
inflammation, in addition to detection of BoDV1 nucleopro-
tein and RNA. Given that some regions were covered by sev-
eral samples, for statistics, the results were pooled to
14 relevant areas. From the aforementioned histopathological
parameters, the general histopathology score was designed to
provide a rough comparison of the inflammatory activity
within different brain regions. For this purpose, all 14 areas
received points for their rank regarding the 5 categories, with
the highest score of 14 for the top rank and a score of 1 for
the lowest rank. The ranking scores of the 5 parameters were
summed to yield a general histopathology score.

**Results**

**Patient and Scan Data**

Complete clinical information was available for 18 of the
19 included patients (mean age 45 ± 23 [range 11–78]
years; detailed clinical data are given in Table 1). Death
occurred in all patients with available data at a mean of
38 ± 22 days after symptom onset. Three patients were
under immunosuppressive therapy (P8, P11, and P14),
whereas the other 16 patients had no relevant underlying
medical conditions. Fever or flu-like episodes were the
most common initial symptoms, apparent in 15 patients.
Ascending tetraparesis (P8), progressive encephalopathic
symptoms (P11), and dysarthria and visual hallucinations
(P17) were the main symptoms on admission of the
3 other patients for whom clinical information was avail-
able. All patients lived in southern Germany, a region
demic for BoDV-1.

A total of 55 MRI scans from the 19 patients (mean
scans per patient = 3.0 [range 1–4]) were available for
analysis. All scans included a T2-weighted or fluid-
attenuated inversion recovery (FLAIR) sequence of diag-
nostic quality; 46 (84%) examinations had diffusion imag-
ing, and 46 (84%) examinations were contrast enhanced.
Fourteen patients were scanned exclusively on 1.5T
machines, 4 patients on 3T machines, and 1 patient
(P2) was scanned on a 1.5T machine for baseline and a
3T machine for follow-up imaging.
### TABLE 1. Summary of Clinical Data

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age at Death, yr</th>
<th>Symptoms at Admission</th>
<th>CSF Findings (Days after Symptom Onset)</th>
<th>Time Until Death, days</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>40–44</td>
<td>Fever, apathy, soporous state</td>
<td>Pleocytosis (4)</td>
<td>26</td>
</tr>
<tr>
<td>2</td>
<td>10–14</td>
<td>Fever, reduced general state, emesis, gait ataxia, enuresis</td>
<td>Pleocytosis (5)</td>
<td>28</td>
</tr>
<tr>
<td>3</td>
<td>70–74</td>
<td>Flu-like, with weakness of the limbs</td>
<td>Pleocytosis (6)</td>
<td>12</td>
</tr>
<tr>
<td>4</td>
<td>10–14</td>
<td>Flu-like, with fever; subsequently, altered general state, headaches, nystagm, gait ataxia, slurred speech and vestibular disorder</td>
<td>Pleocytosis, high protein, glucose and lactate (3)</td>
<td>25</td>
</tr>
<tr>
<td>5</td>
<td>10–14</td>
<td>Fever, seizures, somnolence</td>
<td>Pleocytosis, high protein and lactate, oligoclonal bands, mildly impaired blood–CSF barrier (24)</td>
<td>31</td>
</tr>
<tr>
<td>6</td>
<td>50–54</td>
<td>Fever, progressive confusion syndrome</td>
<td>Pleocytosis, oligoclonal bands, high protein (19)</td>
<td>45</td>
</tr>
<tr>
<td>7</td>
<td>20–24</td>
<td>Flu-like, with fever, headaches, arthralgia, apathy, memory dysfunction</td>
<td>Pleocytosis, oligoclonal bands, intrathecal IgM synthesis, elevated 14-3-3 protein (11)</td>
<td>39</td>
</tr>
<tr>
<td>8</td>
<td>70–74</td>
<td>Ascending tetraparesis, intention tremor of the arms</td>
<td>Pleocytosis, impaired blood–CSF barrier, elevated 14-3-3 protein (37)</td>
<td>96</td>
</tr>
<tr>
<td>9</td>
<td>75–79</td>
<td>Fever, productive cough, reduced general state, with unsteady gait and hemiparesis of the right side</td>
<td>Pleocytosis, high protein and lactate (2)</td>
<td>25</td>
</tr>
<tr>
<td>10</td>
<td>45–49</td>
<td>Flu-like, with headaches, disorientation</td>
<td>Pleocytosis, impaired blood–CSF barrier, elevated 14-3-3 protein (15)</td>
<td>39</td>
</tr>
<tr>
<td>11</td>
<td>65–69</td>
<td>Axonal polyneuropathy, progressive encephalopathic syndrome (or symptoms)</td>
<td>Impaired blood–CSF barrier, no pleocytosis (5)</td>
<td>42</td>
</tr>
<tr>
<td>12</td>
<td>30–34</td>
<td>Flu-like, with headaches</td>
<td>Pleocytosis, high lactate, impaired blood–CSF barrier (4)</td>
<td>31</td>
</tr>
<tr>
<td>13</td>
<td>35–39</td>
<td>Fever, dizziness, nausea, vertigo</td>
<td>Pleocytosis, high lactate, impaired blood–CSF barrier (3)</td>
<td>53</td>
</tr>
<tr>
<td>14</td>
<td>40–44</td>
<td>Flu-like, with headaches and progressive dizziness</td>
<td>Pleocytosis, high lactate, impaired blood–CSF barrier (4)</td>
<td>67</td>
</tr>
<tr>
<td>15</td>
<td>55–59</td>
<td>Flu-like, with progressive delirium</td>
<td>Pleocytosis, high lactate, impaired blood–CSF barrier (12)</td>
<td>16</td>
</tr>
<tr>
<td>16</td>
<td>15–19</td>
<td>Flu-like, with headaches, dizziness, ataxia, and seizures</td>
<td>Pleocytosis, high lactate and protein, elevated 14-3-3 protein (9)</td>
<td>12</td>
</tr>
<tr>
<td>17</td>
<td>65–69</td>
<td>Reduced general state, dysarthria, visual hallucinations</td>
<td>Pleocytosis, impaired blood–CSF barrier, intrathecal IgG synthesis (7)</td>
<td>74</td>
</tr>
<tr>
<td>18</td>
<td>30–34</td>
<td>Flu-like, abdominal pain</td>
<td>Pleocytosis (5)</td>
<td>48</td>
</tr>
<tr>
<td>19</td>
<td>70–75</td>
<td>Flu-like, confusion</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

In conformity with pseudonymization policies, patient age is provided only in 5-year intervals.

CSF = cerebrospinal fluid; NA = no information available; Pleocytosis refers to lymphomonocytic pleocytis.
Pattern and Quantitative Changes on MRI

Of the 19 included patients, 10 (53%) showed imaging abnormalities on baseline MRI. In these scans, acquired at a mean of 11 ± 10 days after symptom onset, a characteristic phenotype was distinguishable, with inflammatory lesions mainly arising from the head of the caudate nucleus in addition to the adjacent insula, thalamus, and operculum in descending frequency. This distinguishable pattern remained intact on follow-up imaging, available for 16 patients at a mean of 26 ± 13 days after symptom onset, with a lesion peak in the head of the caudate nucleus and heterogeneous spread into the adjacent parenchyma and brainstem now becoming more pronounced. Notably, the regions furthest from the basal ganglia (ie, the occipital poles and cerebellar hemispheres) were spared, even in late-stage disease. Figure 1 shows representative examples of this pattern.

Altogether, abnormalities were present in 41 of the 55 included scans and were distributed symmetrically among both hemispheres in 32 (78%) scans. The lesions showed a laterality in 7 (17%) scans and were strictly unilateral in 2 (5%) scans.

Quantitative evaluation of all baseline scans revealed that the count of affected brain regions per patient ranged from 0 to 26, with a group mean of 6.1 ± 8.5 (12.2% of the 50 investigated anatomical areas). Cortical structures were affected in 7 (37%) patients, the subcortical white matter in 4 (21%) patients, the deep white matter in 4 (21%) patients, and the subcortical nuclei in 6 (32%) patients. Anatomically, there was a strong predilection for the basal ganglia and the limbic system, with lesions being most common in the head of the caudate nucleus (7 [37%] patients), insula (6 [32%] patients), and hippocampus and (posteromedially accentuated) thalamus (5 [26%] patients each).

Quantitative evaluation of all follow-up scans revealed that the number of affected brain regions per patient increased sharply to a group mean of 19.3 ± 13.3 (38.6% of the 50 investigated anatomical areas) and ranged from 0 to 42 per patient. Cortical structures were affected in 12 (75%) patients, the subcortical white matter in 4 (25%) patients,
the deep white matter in 7 (44%) patients, and the subcortical nuclei in 14 (88%) patients. By analogy to baseline scans, the head of the caudate nucleus (13 [81%] patients) was most commonly involved, followed by the hippocampus (12 [75%] patients) and insular ribbon (12 [75%] patients). For more detail, the 10 most-affected and 5 least-affected brain regions, with their associated signal changes for the baseline scan and follow-up scan, are presented in Table 2.

Laminar necroses were detectable in none of the index scans and in 5 (32%) patients on follow-up. A frequent phenomenon was the T1-hyperintense transformation of the basal ganglia, occurring in 9 (47%) patients at a mean of 11 \( \pm 8 \) days before death.

Microhemorrhages, as defined by patchy T2* signal loss, were discernable in none of the 55 systematically evaluated scans.

**Time Dependency on Imaging**
The median “time-to-abnormality” on MRI was 12 (interquartile range: 5–21) days after symptom onset and 22 (interquartile range: 15–28) days before death. A pictogram outlining the time-dependent MRI changes is given in Figure 2 and confirms the above-mentioned inflammation pattern in early disease, with subsequent spread into the adjacent parenchyma.

**Correlation with Neuropathology**
To confirm that the patterns described reflect the pathology of human Borna encephalitis, we compared neuropathological changes in 25 brain regions from Patient 4, who was included in a previous study, with imaging findings in an MR scan acquired 2 days before death (Fig 3). The MR scan showed a typical pattern, with T2 hyperintensity of

<table>
<thead>
<tr>
<th>Region</th>
<th>Baseline (n = 19)</th>
<th>Last Scan (n = 16)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Any Lesion</td>
<td>T2 High</td>
</tr>
<tr>
<td>Head of the Caudate Nucleus</td>
<td>7 (36.8%)</td>
<td>5</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>5 (26.3%)</td>
<td>1</td>
</tr>
<tr>
<td>Insula</td>
<td>6 (31.6%)</td>
<td>3</td>
</tr>
<tr>
<td>Parahippocampal gyrus</td>
<td>5 (26.3%)</td>
<td>2</td>
</tr>
<tr>
<td>Temporal pole</td>
<td>4 (21.1%)</td>
<td>2</td>
</tr>
<tr>
<td>Thalamus</td>
<td>5 (26.3%)</td>
<td>2</td>
</tr>
<tr>
<td>Frontal pole</td>
<td>1 (5.3%)</td>
<td>1</td>
</tr>
<tr>
<td>Putamen</td>
<td>4 (21.1%)</td>
<td>3</td>
</tr>
<tr>
<td>Gyrus rectus</td>
<td>2 (10.6%)</td>
<td>2</td>
</tr>
<tr>
<td>Operculum</td>
<td>5 (26.3%)</td>
<td>3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Region</th>
<th>Baseline (n = 19)</th>
<th>Last Scan (n = 16)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Any Lesion</td>
<td>T2 High</td>
</tr>
<tr>
<td>Deep white matter occipital</td>
<td>0 (0%)</td>
<td>0</td>
</tr>
<tr>
<td>Occipital pole</td>
<td>0 (0%)</td>
<td>0</td>
</tr>
<tr>
<td>Optic nerves</td>
<td>0 (0%)</td>
<td>0</td>
</tr>
<tr>
<td>Pineal gland</td>
<td>0 (0%)</td>
<td>0</td>
</tr>
<tr>
<td>Cerebellar hemisphere</td>
<td>1 (5.0%)</td>
<td>1</td>
</tr>
</tbody>
</table>
the basal ganglia, whereas the occipital lobe seemed not to be affected. In line with this observation, histology revealed marked changes in the basal ganglia, with strong perivascular and diffusely distributed CD45+ lymphocytic infiltrates. GFAP- and Iba1-immunohistochemistry showed strong astroglial and microglial activation. Several cells with a positive signal for BoDV-1 RNA could be detected. In contrast, the occipital lobe showed only minimal inflammation. Nevertheless, it was notable that there were few perivascular lymphocytic infiltrates and the beginning of formation of microglial nodules.

To quantify the correlation between imaging and neuropathology, we defined a “general histopathology score,” as explained in the Patients and Methods section. In this score, and by analogy to the aforementioned MRI phenotype, a clear pattern became evident, with the striatum and head of the caudate nucleus being most affected, followed by the limbic regions and insula. In contrast, and reproducing the gradient that was distinguishable on MRI, the cerebellar hemispheres and the occipital lobe showed the lowest inflammation. See Table 3 for the general histopathology score of each region.

FIGURE 2: Pictograms with a color-based inflammation pattern of selected brain regions, illustrated for the first scan (available for 19 patients at a mean of 11 ± 10 days after symptom onset) and the follow-up scan (available for 16 patients at a mean of 26 ± 13 days after symptom onset). T1-hyperintense transformation of the basal ganglia was noted in 9 patients at a mean of 11 ± 8 days before death.
Detailed quantitative readings showed that the highest number of Joest–Degen inclusion bodies was observed in the left striatum (7 of 10 HPFs), followed by the left head of the caudate nucleus and the frontal cortex (each 6 of 10 HPFs). The lowest numbers were seen in the cerebellar hemispheres (0 of 10 HPFs) and the samples of the occipital lobe (average 1 of 10 HPFs).

The highest edema score was reached in the temporal pole and parietal cortex (each scoring 3). No remarkable edema was detected in the cerebellar hemisphere (average score 0.5).

The highest number of reactive astrocytes was found in the thalamus (average 48.8 per HPF), followed by the striatum (average 41.8 per HPF) and the frontal cortex (average 40.8 per HPF). Notably, the activated astrocytes observed were often bizarrely enlarged and of gemistocytic and coarse appearance. The mildest astrogliosis was seen in the deep white matter (average 21.8 per HPF), mesencephalon (average 22 per HPF), and cerebellar hemispheres (average 23.7 per HPF).

The striatum showed the highest amount of activated microglial cells (average 199.2 per HPF), followed by the parietal cortex (average 102 per HPF). The cerebellar hemispheres (average 19.9 per HPF) and the occipital lobe (average 35 per HPF) were least affected by microglial activation.

Most diffusely distributed lymphocytes were present in the striatum (581 lymphocytes/cm²) and the thalamus (486/cm²). Frontal and parietal cortex showed least diffuse inflammation (41 and 44/cm², respectively). The strongest perivascular infiltrate was also seen in the striatum (average 75 per vessel) and the head of the caudate nucleus (average 68 per vessel). The lowest numbers were found in the cerebellar hemispheres (average 8 per vessel) and frontal cortex (average 19 per vessel).

Most BoDV-1 nucleoprotein+ cells were detected in the striatum (128/cm²) and the head of the caudate nucleus (103/cm²), whereas the thalami and the cerebellar hemispheres were negative for the virus protein. The highest number of BoDV-1 RNA-positive cells was counted in the insula (158.3 positive cells/cm²) and parietal

![FIGURE 3: Comparison of histopathology with magnetic resonance imaging (MRI) abnormalities. (A) MRI of Patient 4 shows T2 hyperintensity of the basal ganglia, whereas the occipital lobe seems not to be affected. (B) In line with this observation, histology reveals marked changes in the basal ganglia, with strong perivascular (a) and diffusely distributed (d) CD45+ lymphocytic infiltrates. GFAP- and Iba1-immunohistochemistry shows strong astroglial (b) and microglial activation. Several cells with a positive signal for Borna disease virus (BoDV-1) RNA can be detected (e). (C) In contrast, the occipital lobe shows only minimal inflammation. Nevertheless, it is notable that there are few perivascular lymphocytic infiltrates (a) and the start of formation of microglial nodules (c). (D, E) The histopathological correlate for the described strong T1-hyperintensity of the basal ganglia, shown in D, is a massive accumulation of CD68+ macrophages, shown in E. (G) Note the fusiform positivity for BoDV-1 nucleoprotein (Bo18) in the cerebellar vermis, otherwise with complete negativity of the cerebellum (not shown), indicating an incipient infiltration by the virus. Scale bars: 50μm in Ba and Be; 200μm G; 20μm in all other panels.](image-url)
No viral RNA was detected in the occipital and frontal cortex or in the cerebellar hemispheres.

**Histopathological Correlate of T1 Hyperintensity of the Basal Ganglia**

Given that a strong T1 hyperintensity of the basal ganglia developed in 9 patients, histopathological analysis was also focused on outstanding changes in this area. Remarkably massive accumulation of lipid phagocytes was observed in the basal ganglia of Patient 4. CD68+ macrophages were also detected in other regions, but nowhere else at such high density, as illustrated further in Figure 3.

**Discussion**

Despite broad research surrounding BoDV-1 disease in horses and sheep, attention to the potential zoonotic spillover from the small mammal reservoir to humans has grown only recently, owing to the rising number of confirmed human infections in virus-endemic regions. As far as we know, BoDV-1 disease in humans shows strong similarities to the BoDV-1 infections in animals, with rapidly progressive symptoms and exceedingly high fatality rates.1–4 A recently published retrospective analysis showed that a high fraction of initially non-classifiable fatal encephalitis cases was attributable to BoDV-1.5 Given that clinical symptoms are often not
discernible from other neurological diseases, early identification of affected patients through widely available imaging would be most valuable to enable earlier engagement in potential therapies and to facilitate delineation from differential diagnoses. In this study, we provide the first comprehensive insight into the MRI abnormalities and their histopathologic correlates for the largest cohort so far of 19 patients with confirmed BoDV-1 encephalitis.

In agreement with the pre-reported viral tropism in animal models, we found a typical imaging pattern in both the early and late stages of human BoDV-1 disease. As such, a distinct pattern of inflammation, with predominantly symmetric T2 hyperintensities affecting the head of the caudate nucleus, posteromedial thalamus, insular ribbon, and hippocampus in the early stages of disease, was clearly distinguishable on baseline MRI. In the later stages of the disease, this characteristic morphology remained intact as inflammation then spread diffusely into the adjacent parenchyma (especially frontal/temporal) and brainstem. Consistent with an inflammation spread “per continuatatem,” the lateral cerebellar hemispheres and occipital poles, farthest away from the brain regions initially affected, remained largely unaffected until the final stages of the disease. Accompanying diffusion restriction of the T2-hyperintense lesions was common, as a possible surrogate for cytotoxic edema, whereas the blood–brain barrier was intact in most cases.

The dynamics of this pattern confirm previously published animal studies that showed a strong tropism of Bornaviridae for the cortical and subcortical gray matter, with only marginal white-matter involvement. Although the clear path of infection and potential zoonotic spread still remain opaque, a theory of intranasal virus transmission with retrograde transaxonal migration to the brain has been proposed in horses and experimentally infected rats. Speculative causes for this olfactory susceptibility include the direct contact of the olfactory nerves with the environment in addition to the lack of protective nerve sheathing, with a consequently delayed immune response. Partly in line with these reports, and keeping in mind that the olfactory bulb per se is difficult to visualize on MRI, the gyrus rectus that runs along the olfactory bulb showed a common and early inflammatory involvement. Nonetheless, the alterations herein seem to have spread secondarily from the basal ganglia and not vice versa. Although highly speculative, the above-mentioned pattern of encephalitis on MRI could hence be explained more readily by an inflammation seeding through hematogenous rather than retrograde transaxonal spread.

Although the distribution pattern, with a predilection for the basal ganglia, can help in the differentiation from the more common herpes simplex virus type 1 (HSV-1) or autoimmune encephalitis, the lack of microhemorrhages differs from a typical late-stage finding in both HSV-1 and Japanese encephalitis. The symmetric inflammation pattern in Borna encephalitis can also facilitate differentiation from HSV-1 encephalitis, in which mostly asymmetric involvement of the temporal lobes can be seen.

In spite of the generally biphasic and benign course of tick-borne encephalitis, its overlapping endemic regions and comparable flu-like initial symptoms can mimic the characteristics of BoDV-1 encephalitis. MRI abnormalities, which occur in only a minority of tick-borne encephalitis cases, can be seen in the thalamus and basal ganglia, but often also manifest themselves in the infratentorial region, with typical alterations of the cerebral crus and cerebellum. The frequently associated leptomeningeal contrast enhancement and lack of parenchymal restriction of diffusion also facilitate differentiation from BoDV-1 encephalitis (for comparison of BoDV-1 encephalitis with differential diagnoses, see Table 4).

Strikingly, the preference for the head of the caudate nucleus and striatum, with regularly associated restriction of diffusion along the cortical band (apparent in one-quarter of both early- and late-stage BoDV-1 encephalitis cases), resembles the typical MRI appearance of sporadic Creutzfeldt–Jakob disease (sCJD). Further analogies with sCJD, such as the dramatically high lethality rates, are, however, counterbalanced by the faster disease course, with flu-like symptoms, in BoDV-1 encephalitis and the fact that imaging abnormalities tend to occur much earlier in the course of sCJD versus BoDV-1 encephalitis. Furthermore, the occasional contrast enhancement of encephalitic lesions in BoDV-1 patients is an MRI phenomenon practically never encountered in sCJD. Although 14-3-3 protein could be detected in 4 of the 16 patients in whom this test was performed, the sometimes-held conviction of its specificity for sCJD has long been rebutted, because this cerebrospinal fluid (CSF) marker is known to increase in various types of conditions with severe neurological damage, such as encephalitis.

Rapidly occurring death in BoDV-1 encephalitis renders reliable comparison with the fulminating brain atrophy in sCJD impossible. Nonetheless, the T1-hyperintense transformation of the basal ganglia (an unexpected observation made in nearly half of our patients), which has also been reported in sCJD, deserves consideration. Explanations for this phenomenon in the basal ganglia are manifold and curving, but the shortened longitudinal relaxation and subsequent increase in T1 signal can, in summary, be attributed to heightened tissue concentrations of either fat or paramagnetic ions, such as manganese or ferrous blood compounds. As shown by the dynamics on MRI, it seems...
<table>
<thead>
<tr>
<th>Entity</th>
<th>Symptoms</th>
<th>1. Similar features to BoDV-1 encephalitis on MRI</th>
<th>2. Different features from BoDV-1 encephalitis on MRI</th>
<th>Natural course</th>
</tr>
</thead>
<tbody>
<tr>
<td>BoDV-1 encephalitis</td>
<td>Flu-like symptoms, fever. Gait ataxia, dysphagia, blurred speech, hemiparesis, seizures</td>
<td>1. Latency of imaging abnormalities to clinical symptoms. Characteristic appearance, with initial predilection for the head of the caudate nucleus, insula, striatum and limbic regions. Subsequent spread, with typical sparing of the occipital region and cerebellar hemispheres. T1-hyperintense transformation of the basal ganglia in late-stage encephalitis</td>
<td>2. Not applicable</td>
<td>Rapidly progressing, with death occurring at a mean of 40 days</td>
</tr>
<tr>
<td>sCJD</td>
<td>Rapid cognitive decline, ataxia, akinetic muscular mute state</td>
<td>1. T2w- and DWI abnormalities of the cerebral cortex, usually sparing the peritiorinal area. Involvement of the caudate nucleus and putamen, with anterior-to-posterior gradient. T2w hyperintensities of the pulvinar (sCJD)</td>
<td>2. Changes may precede clinical symptoms. Rapidly progressing (cerebellar) atrophy. Involvement of the occipital cortex and generally sparing the insula.</td>
<td>Fatal condition, with death occurring at a mean of 6 mo</td>
</tr>
<tr>
<td>HSV-1</td>
<td>Prodromal state with fever, followed by seizures, abnormal behavior, disorientation</td>
<td>1. T2w hyperintensity and diffusion restriction in the mesiotemporal and frontal lobes</td>
<td>2. Basal ganglia tend to be spared. Mostly asymmetric. Changes usually visible 2–3 days after symptom onset. T2* blooming as microhemorrhages occur</td>
<td>70% mortality if untreated, neuropsychiatric deficits common</td>
</tr>
<tr>
<td>Japanese encephalitis</td>
<td>From nonspecific febrile illness to poliomyelitis-like paralysis</td>
<td>1. Symmetric T2w hyperintensity, generally without restricted diffusion (in the acute stage) of the thalamus, basal ganglia and the brainstem. T1-hyperintense basal ganglia, attributable to hemorrhage. MRI can be negative ≤3 weeks after symptom onset</td>
<td>2. T2* blooming in the later stages.</td>
<td>Neuropsychiatric sequelae in 50%, death in 25–30% of cases</td>
</tr>
<tr>
<td>Dengue encephalitis</td>
<td>Fever, headache, retro-orbital pain. Myalgia and arthralgia</td>
<td>1. Involvement of the bilateral thalami, pulldum, temporal lobe, and hippocampus, with T2w hyperintensity, variable diffusion restriction, and variable contrast enhancement</td>
<td>2. Lack of imaging abnormalities in ≤42% of cases</td>
<td>Self-limiting, with good patient recovery in most cases</td>
</tr>
<tr>
<td>Tick-borne encephalitis</td>
<td>Biphasic clinical course with initial flu-like symptoms</td>
<td>1. T2-hyperintense lesions in the thalamus (especially pulvisart), putamen, and cns cerebel.</td>
<td>2. Imaging abnormalities in only a minority of cases. Affection of the cerebellum. Leptomeningeval enhancement. No parenchymal diffusion restriction</td>
<td>Mostly favorable outcome</td>
</tr>
<tr>
<td>West Nile encephalitis</td>
<td>Fever/hypothermia, encephalopathy, acute onset of limb weakness</td>
<td>1. Predilection for deep gray matter structures and basal ganglia. Diffusion restriction common. Normally, no contrast enhancement</td>
<td>2. Involvement of the brainstem and cerebellum. No findings on neuroimaging in ≥30% of cases</td>
<td>High short-term mortality (18%), only 21% returning to previous levels of function</td>
</tr>
</tbody>
</table>

The table shows the typical respective symptoms, commonalities, and differences on MRI, in addition to the natural disease course.

BoDV-1 = classical Borna disease virus, species *Mammalian 1 orthobornavirus*; HSV-1 = herpes simplex virus type 1; MRI = magnetic resonance imaging; sCJD = sporadic Creutzfeldt–Jakob disease; vCJD = variant Creutzfeldt–Jakob disease.
plausible that inflammation and thus tissue damage in BoDV-1 encephalitis is most prominent in the basal ganglia. Taken together with histological analyses that have confirmed a high concentration of macrophages in these regions, we hypothesize that late-stage necrosis leads to a transformation of microglia into lipid phagocytes and thus translates to this characteristic imaging appearance, a phenomenon previously known to occur in hypoxic–ischemic brain injury.²⁴

In conclusion, this study provides the first comprehensive insight into the MRI morphology of BoDV-1 encephalitis. A characteristic pattern can be identified in both the early and late stages of the disease, with inflammation spreading from the head of the caudate nucleus, striatum, insula, and limbic system into the surrounding parenchyma. T1-hyperintense transformation of the basal ganglia, insula, and limbic system into the surrounding parenchyma. T1-hyperintense transformation of the basal ganglia, insula, and limbic system into the surrounding parenchyma. T1-hyperintense transformation of the basal ganglia, insula, and limbic system into the surrounding parenchyma. T1-hyperintense transformation of the basal ganglia, insula, and limbic system into the surrounding parenchyma.

Although it is pathophysiologically different, the similar MRI features and equally devastating clinical course render differentiation from sCJD difficult and raise the question of whether BoDV-1 might be found retrospectively in prion-suspected brain samples that tested negative for sCJD.

Acknowledgments
No funding source was involved in the conception or carrying out of this study. This study is dedicated to Georg Gosztonyi, a pioneer in Borna-related research.

We thank Thomas Ebersberger and Hans-Peter Dinkel for contributing MRI studies of 3 patients from community hospitals. We are also grateful for the support of Bernhard Neumann, who supplied clinical data of some patients. Open access funding enabled and organized by Projekt DEAL.

Author Contributions
Conception and design of study: C.Z., C.W., B.W., I.W., F.L.-S., T.F., F.D., J.S., and M.P. Data acquisition and analysis: F.L.-S., I.W., M.P., T.F., V.R., K.A., S.B., F.D., B.W., and C.Z. Drafting of the manuscript: T.F., F.L.-S., I.W., B.W., and C.Z. All authors have read and approved the final manuscript.

Borna-virus-Encephalitis Study Group: Drs A. Berlis, C. Maurer, M. Holtmannspötter, S. Wunderlich, M. Rosati, and D. Rubbenstroth.

Potential Conflicts of Interest
The authors have no conflicts of interest to report.

References


